Korean J Dermatol.  2019 Nov;57(9):551-555.

Lichen Planus Developed During the Treatment with Nivolumab in a Patient with Lung Cancer: A Case Report and Literature Review

Affiliations
  • 1Department of Dermatology, Veterans Health Service Medical Center, Seoul, Korea. serratus40@gmail.com

Abstract

Nivolumab is a fully-humanized IgG4 monoclonal antibody that competitively binds to the programmed cell death receptor-1 protein (an immune check-point molecule) present on activated T cells. Nivolumab is approved for the treatment of advanced melanoma, lung cancer, and renal cell carcinoma. It attenuates the inactivation of cytotoxic CD8+ T cells and, produces an antitumor effect; however it may be associated with immune-related adverse events, including the development of lichen planus (LP). A 72-year-old man presented with a 2-month history of multiple, polygonal, purplish papules on the dorsal aspect of both hands. He was diagnosed with large cell neuroendocrine carcinoma (LCNEC) of the lung 4 years earlier and was treated with nivolumab (3 mg/kg every 2 weeks) for 9 months. By the 14th course of nivolumab therapy, the patient developed multiple rashes on the dorsal aspect of both hands, and biopsy was consistent with findings of LP. We report a rare case of LP in a patient with lung cancer treated with nivolumab.

Keyword

Anti-programmed cell death receptor-1 antibody; Anti-PD-1 antibody; Lichen planus; Nivolumab

MeSH Terms

Aged
Biopsy
Carcinoma, Neuroendocrine
Carcinoma, Renal Cell
Cell Death
Exanthema
Hand
Humans
Immunoglobulin G
Lichen Planus*
Lichens*
Lung Neoplasms*
Lung*
Melanoma
T-Lymphocytes
Immunoglobulin G
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr